Company Contact – Chris Englerth
Bioclinica, Inc.
484-928-6740
Trade Media − Allie Seifert
DDCworks484-342-3600

Bioclinica Provides Risk-Based Monitoring Solution in JapanEPS to Run Clinical Studies Using COMPASSDOYLESTOWN, Pa., Jan. 25, 2016 – Bioclinica®, Inc., a specialty clinical trials technology andservices provider, today announced Japanese CRO, EPS Corporation (EPS), has selected Bioclinica
COMPASS technology and professional services as its risk-based monitoring (RBM) solution forclinical trials in Japan.
“We are thrilled that EPS, with a reputation as Japan’s most progressive CRO, has chosen Bioclinica
to pioneer RBM,” said Bioclinica Senior Vice President of Product Development and Technology
Andrew Masters. “We provide a complete integrated software solution aimed at satisfying risk-averseCROs and sponsors. This includes giving EPS the ability to track Key Risk Indicators across their
entire study portfolio. Centralized monitoring with COMPASS is a better, more cost-effective way tomonitor clinical trials, and aims to improve site performance and overall study quality.”“EPS has been eager to implement effective RBM services consistent with MHLW/PMDA, FDA andEMA initiatives − one capable of handling our volume and diversity in studies,” said EPS President
and Representative Director Hisashi Tanaka. “From our comprehensive survey of commerciallyavailable RBM technologies, we concluded that our RBM services with Bioclinica COMPASS andcomprehensive technology and professional services would best meet the intent of RBM, while
addressing all three factors critical for successful RBM services − people, process and technology –together in an RBM SaaS solution with exceptional data integration capabilities.”
Bioclinica offers a feature-rich RBM solution with a library of 44 standard KRIs and an ability to add
additional custom KRIs. Tracking and visualization at the study and site level, combined with robust
alert and action recommendations, stood out over competing systems in extensive evaluation andsandbox testing, according to Tanaka. “When we looked at configurability, ease of deployment, ability
to connect to existing eClinical systems and overall flexibility of the solution to meet our needs,
COMPASS came out ahead as the RBM enterprise solution for us.”
Masters explained, “Data integration is the backbone of successful RBM analytics. COMPASS was
specifically designed to process operational and patient data from EDC, CTMS, RTSM and othersource systems with little configuration, providing users the utmost confidence in our RBM analytics.”−more−

“We expect our comprehensive RBM solution to make a marked and tangible difference in the abilityof EPS to view and manage KRIs”, Masters added. COMPASS provides study teams with earlyvisibility into site and patient trends for improved data quality and oversight of trials, reducing costs
through centralized, technology-enabled monitoring.
Study managers, monitors and other EPS team members are participating in a comprehensive
training program. “We want to ensure our customers become as adept at using COMPASS as ownteam,” Masters said. “Bioclinica is shifting the paradigm to technology enablement, making CROs
autonomous.”
Implementation of Bioclinica COMPASS and associated RBM professional services is underway withthe technology rolling out on live studies in coming months. “EPS is looking forward to working with
Bioclinica in this technologically innovative RBM era to contribute to pharmaceutical productdevelopment,” Tanaka said.
Find out more about Bioclinica and its support of standards in clinical trials on the Trial Blazers blog at
http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.
About EPS Corporation
EPS is a 100 percent subsidiary company of EPS Holdings Inc. (TYO: 4282) and part of a largeorganization within the EPS Group. EPS is one of the leading companies of CRO (Contract ResearchOrganization) services providing full support – from the planning of clinical trials to post-marketingsurveillance – for the development pursuits of pharmaceutical companies, in Japan.
Learn more at http://www.eps-holdings.co.jp/en/about/network.html and http://www.eps.co.jp/.
About Bioclinica
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in theclinical trial process. Bioclinica is organized by three business segments to deliver focused service
supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides
medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth
Solutions segment comprises an eClinical technology platform and professional services along withsafety and regulatory solutions. Under the Global Clinical Research segment, Bioclinica offers anetwork of research sites, patient recruitment-retention services, and a post-approval researchdivision. The Company serves more than 400 pharmaceutical, biotechnology and deviceorganizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.
Learn more at www.bioclinica.com.
###